SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Scinai Immunotherapeutics Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$0.75−0.00 (-0.32%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Scinai Immunotherapeutics Ltd. revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Scinai Immunotherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.